hVIVO is set to run the world’s first Phase 3 human challenge trial for a new whooping cough vaccine. Scheduled for late 2025, this will be their largest trial to date.
Meanwhile, Solvonis Therapeutics has reported that takeover target Awakn Life Sciences is making huge strides in treatments for mental health disorders. AWKN-001 cut heavy drinking by 50% and achieved 86% abstinence, while AWKN-002 and AWKN-SND-14 are advancing alcohol addiction and PTSD therapies.
Genel Energy has reported strong cash flow and production from the Tawke fields in Kurdistan for its 2024 financial year. The company’s net cash rose to $131 million, setting the stage for growth in 2025.
Active Energy Group has overhauled its board, appointing two experienced directors. Property developer Paul Elliott and finance specialist Pankaj Rajani are now on board.
Finally, Pantheon International’s net asset value increased slightly in December, driven by strong cash generation. Distributions of £72.3 million far outweighed commitments, adding nearly £47 million in net cash.
Follow us and subscribe on Youtube, our social channels and of course on proactiveinvestors.co.uk.
